The world according to covid vaccine coverage

Looi, Mun-Keat

doi:10.1136/bmj.n2732

Cited by 6 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Containment and mitigation measures as well as the vaccine campaign cannot reach their full potential for pandemic control if they are not accepted and followed by almost all of the population. However, only 68% of Germany’s population is fully vaccinated (78.6% among adults; November 21 th 2021), which, even considering an estimated underreporting of up to 5 percentage points 67 , is not sufficient and lags behind other Western European countries 68 . As the RKI-SOEP study set out to investigate social and regional aspects and factors that promote or hinder coronary infection and vaccine acceptance, it launched a second round in November 2021, again studying a representative sample of the population in Germany and this time differentiating vaccine- and infection-induced antibodies.…”

Section: Discussionmentioning

confidence: 99%

Germany’s low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study

Neuhauser

Rosario

Butschalowsky

et al. 2021

Preprint

View full text Add to dashboard Cite

Pre-vaccine SARS-CoV-2 seroprevalence data from Germany are scarce outside hotspots, and socioeconomic disparities remained largely unexplored. The nationwide RKI-SOEP study with 15,122 adult participants investigated seroprevalence and testing in a supplementary wave of the Socio-Economic-Panel conducted predominantly in October-November 2020. Self-collected oral-nasal swabs were PCR-positive in 0.4% and Euroimmun anti-SARS-CoV-2-S1-IgG ELISA from dry capillary blood in 1.3% (95% CI 0.9-1.7%, population-weighted, corrected for sensitivity=0.811, specificity=0.997). Seroprevalence was 1.7% (95% CI 1.2-2.3%) when additionally adjusting for antibody decay. Overall infection prevalence including self-reports was 2.1%. We estimate 45% (95% CI 21-60%) undetected cases and analyses suggest lower detection in socioeconomically deprived districts. Prior SARS-CoV-2 testing was reported by 18% from the lower educational group compared to 25% and 26% from the medium and high educational group (p<0.0001). Symptom-triggered test frequency was similar across educational groups. However, routine testing was more common in low-educated adults, whereas travel-related testing and testing after contact with an infected person was more common in highly educated groups. In conclusion, pre-vaccine SARS-CoV-2-seroprevalence in Germany was very low. Notified cases appear to capture more than half of infections but may underestimate infections in lower socioeconomic groups. These data confirm the successful containment strategy of Germany until winter 2020.

show abstract

Section: Discussionmentioning

confidence: 99%

Germany’s low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study

Neuhauser

Rosario

Butschalowsky

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Many national governments limited social interactions and restrained economic activities to mitigate COVID-19 transmission, leading to isolation and hardship. The rapidly emerging new variants of concern, such as Delta and Omicron, create new challenges for countries even with a high vaccination rate [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Vertical outbreak of COVID-19 in high-rise buildings: The role of sewer stacks and prevention measures

Guo¹,

Li²,

Luby³

et al. 2022

Current Opinion in Environmental Science & Health

View full text Add to dashboard Cite

“…By March 2022, more than 11 billion doses had been administered globally 4 . However, 37% of the world’s population remain unvaccinated, with low vaccination rates in many low-income countries 5 , 6 . Previous infection also confers protection against re-infection 7 , 8 .…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

et al. 2022

View full text Add to dashboard Cite

Given high SARS-CoV-2 incidence, coupled with slow and inequitable vaccine roll-out in many settings, there is a need for evidence to underpin optimum vaccine deployment, aiming to maximise global population immunity. We evaluate whether a single vaccination in individuals who have already been infected with SARS-CoV-2 generates similar initial and subsequent antibody responses to two vaccinations in those without prior infection. We compared anti-spike IgG antibody responses after a single vaccination with ChAdOx1, BNT162b2, or mRNA-1273 SARS-CoV-2 vaccines in the COVID-19 Infection Survey in the UK general population. In 100,849 adults median (50 (IQR: 37–63) years) receiving at least one vaccination, 13,404 (13.3%) had serological/PCR evidence of prior infection. Prior infection significantly boosted antibody responses, producing higher peak levels and/or longer half-lives after one dose of all three vaccines than those without prior infection receiving one or two vaccinations. In those with prior infection, the median time above the positivity threshold was >1 year after the first vaccination. Single-dose vaccination targeted to those previously infected may provide at least as good protection to two-dose vaccination among those without previous infection.

show abstract

The world according to covid vaccine coverage

Cited by 6 publications

References 0 publications

Germany’s low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study

Germany’s low SARS-CoV-2 seroprevalence confirms effective containment in 2020: Results of the nationwide RKI-SOEP study

Vertical outbreak of COVID-19 in high-rise buildings: The role of sewer stacks and prevention measures

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

Contact Info

Product

Resources

About